← Human Trials & Peer-Reviewed Studies
Effects of cefaclor on gastric emptying and cholecystokinin release in healthy humans
Plain-language guide to PMID 19914303 (2010): double-blind randomized controlled trial study of Cholecystokinin (CCK) in 8 subjects.
Key Facts
- PMID
- 19914303
- Journal
- Regulatory peptides
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Ma J et al. (7 authors)
- DOI
- 10.1016/j.regpep.2009.11.009
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Cholecystokinin (CCK), published as a randomized controlled trial.
In rodents, cephalosporin antibiotics can mimic peptones and stimulate release of cholecystokinin (CCK), a hormone that slows gastric emptying.
The rate of gastric emptying is a major determinant of postprandial blood glucose and insulin concentrations.
The researchers therefore evaluated the effect of orally administered cefaclor on plasma CCK and gastric emptying, as well as postprandial glycemic and insulinemic responses, in healthy humans.
Who Took Part
According to the abstract, 8 subjects were involved.
PubMed indexes the participants as adults, both men and women.
How the Study Was Run
In design terms this was a randomized, double-blind and placebo-controlled study.
The subjects were allocated by chance, so the Cholecystokinin (CCK) group and the comparison group should start out alike.
Neither the subjects nor the staff measuring them knew who was on Cholecystokinin (CCK), so expectations could not easily colour the readings.
A placebo (an inactive look-alike) gave the Cholecystokinin (CCK) group a baseline to be compared against.
Blood and breath samples were collected for 4h after the meal.
What Was Measured
Topics PubMed links to this paper include Anti-Bacterial Agents, Blood Glucose, Caprylates, Carbon Isotopes, Cefaclor, Cholecystokinin and Gastric Emptying.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Cholecystokinin (CCK) in 8 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
Its findings take up roughly 3 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2010 (Regulatory peptides), a journal based in Netherlands.
More context: the Cholecystokinin (CCK) compound page, all human trials.
Our Notes on the Compound
Cholecystokinin (CCK): A gut and brain peptide hormone that stimulates gallbladder contraction and signals fullness.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.